Toward disease-modifying therapies in type 1 diabetes: focus on teplizumab
Mathieu C, Sims EK, Chatenoud L, et al.
Diabetes Care. Pub. online 6 Nov 2025.
Leggi
Hemoglobin A1c time-in-range, mortality, and diabetes complications in older adults with diabetes
Conlin PR, Prentice JC, Mohr DC, et al.
BMJ Open Diabetes Res Care. Pub. online 4 Nov 2025.
Leggi
Associations between gestational diabetes and cardiovascular disease largely operate independently of postpartum causal pathways: a population-based cohort study in England
Astbury NM, Ripullone K, Ramakrishnan R, et al.
Diabetes Obes Metab. Pub. online 5 Nov 2025.
Leggi
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet MHA, Nardone M, Rensen PCN, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
Associations between gestational diabetes and cardiovascular disease largely operate independently of postpartum causal pathways: a population-based cohort study in England
Astbury NM, Ripullone K, Ramakrishnan R, et al.
Diabetes Obes Metab. Pub. online 5 Nov 2025.
Leggi
Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
le Roux CW, Wharton S, Bozkurt B, et al.
Diabetes Obes Metab. Pub. online 4 Nov 2025.
Leggi
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Muskiet MHA, Nardone M, Rensen PCN, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Billings LK, Hsia S, Bays H, et al.
Lancet. Pub. online 6 Nov 2025.
Leggi
